Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darceline in HR-positive advanced breast cancer (real-world, safety and efficacy)
ChiCTR2200058860Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Apr 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of darceline in breast cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Adverse events (AE) and Severe adverse events (SAE). Planned start Apr 2022; status: not yet recruiting.
02
Drugs
darceline
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200058860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058860.